Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Tumor nucleic acid vaccine based on tissue factor as well as preparation method and application of vaccine

A tumor nucleic acid vaccine and tissue factor technology, applied in the field of preparation and nucleic acid vaccines, can solve problems such as difficult process, complex protein structure, allergic reaction, etc.

Active Publication Date: 2014-02-12
JIANGSU HIGH WIT BIOTECH CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, they use the whole TF protein as the target and use antibodies or FVII for treatment, which has the disadvantages of complex protein structure, difficult process, and easy triggering of allergic reactions in the body.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor nucleic acid vaccine based on tissue factor as well as preparation method and application of vaccine
  • Tumor nucleic acid vaccine based on tissue factor as well as preparation method and application of vaccine
  • Tumor nucleic acid vaccine based on tissue factor as well as preparation method and application of vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1: Construction of eukaryotic expression vector pCR-X8-HBcΔ-TF

[0021] 1.1 Construction of eukaryotic expression vector pCR-X8-HBcΔ-TF

[0022] 1.1.1 Cloning of TF target gene

[0023] Gene cloning of TF target fragment

[0024] Design upstream and downstream primers as templates for each other, and obtain target fragments by PCR

[0025] TF

[0026] Upstream primer TF-up: 5'- T GGT ACC GGT GAC TGG AAA TCC AAA TGC TTC TAC ACT ACT GAC A-3' (SEQ ID NO: 2)

[0027] Downstream primer TF-down: 5'- AAA AAGC TTA ACC GGT TTC GTC AGT CAA GTC GTA TTC AGT GTC AGT AGT GTA GAA GCA T-3' (SEQ ID NO: 3)

[0028] Both upstream and downstream primers contain restriction endonuclease AgeI sites (indicated by the shaded part)

[0029] PCR reaction system:

[0030] 10×PFU PCR buffer 10 μl

[0031] TF cDNA 2 μl

[0032] 10×PFU PCR buffer 10 μl

[0033] Upstream primer 8 μl

[0034] Downstream primer 8 μl

[0035] dNTP 8 μl

[0036] PFU DNA Polymerase 1 μl

[0...

Embodiment 2

[0067] Example 2: ELISA detection and Western blot detection of TF antibody

[0068] 2.1 Materials

[0069] 2.1.1 Experimental animals

[0070] C57 / BL6 pure line mice, female, 6-8 weeks old, with an average body weight of 16.8 g before immunization, were purchased from the Experimental Animal Center of Yangzhou University.

[0071] experimental drug

[0072] Recombinant nucleic acid vaccine HBcΔ-TF.

[0073] Materials and Reagents

[0074] Purified recombinant proteins VEGF-TFh, VEGF-TFM, VEGF-PVH, VEGF-PVM. The specific test operation is the same as before.

[0075] Materials and Reagents

[0076] Purified recombinant proteins VEGF-TF, VEGF-PV. The specific test operation is the same as before.

[0077] method

[0078] 2.2.1 Immunization program

[0079] C57BL / 6J female mice were selected and divided into random groups, 10 mice in each group, including normal saline control group, plasmid vector control group and pCR-X8-HBcΔ-TF group. Nucleic ac...

Embodiment 3

[0089] Example 3: Research on anti-tumor effect of recombinant TF subunit epitope nucleic acid vaccine

[0090] 3.1 Tumor cell culture and transplantation tumor model preparation

[0091] 3.1.1 Materials

[0092] B16-F10 was purchased from the Institute of Cells, Chinese Academy of Sciences, RPMI1640 and DMEM medium were purchased from JIBCOL, and C57 / BL6 mice were purchased from the Comparative Medicine Center of Yangzhou University.

[0093] Cell Culture and Transplantation

[0094] B16-F10 is a highly metastatic melanoma strain with a C57 / BL6 background, and it is also an adherent growth cell. The culture medium is DMEM medium containing 10% calf serum, and it is inoculated in a culture flask. 5%CO 2When the cells grow into a continuous monolayer under certain conditions, carefully pour off the medium, gently wash with D-HANKS solution, pour off the D-HANKS solution, and add 0.125% trypsin to digest. Pour off the trypsin, immediately add 10% calf serum 1640 m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a tumor nucleic acid vaccine based on a tissue factor, wherein a plasmid is used as a vector; the plasmid is interpolated with a DNA sequence for coding HBc, and the sequence is interpolated with a DNA sequence for coding a human-source TF target epitope polypeptide; sequence of the human-source TF target epitope polypeptide is represented in SEQ ID NO: 1, and the polypeptide is amino acid at position 74-94 of human-source TF; and an ISS sequence is included in a non-coding region of the plasmid vector. Furthermore, the invention discloses a preparation method and an application of the tumor nucleic acid vaccine. The tumor nucleic acid vaccine, through genetic engineering means, presents a sequence selected from TF and including an epitope target point onto a reconstructed hepatitis B core antigen to construct an antigen epitope nucleic acid vaccine; the antigen epitope nucleic acid vaccine is applied to a body through intramuscular injection, so as to promote expression of polypeptide including a TF target epitope, and to stimulate active immunity of the body, thus preventing and treating tumors.

Description

technical field [0001] The invention relates to a nucleic acid vaccine, a preparation method and its application, especially a tumor nucleic acid vaccine, a preparation method and its application. Background technique [0002] The coagulation function of tissue factor (TF) is well known. After it combines with activated coagulation factor VII (activated factor VII, F VIIa), it forms a complex of TFPF VIIa to initiate the extrinsic coagulation pathway; it can also activate coagulation factor XI, Activate the intrinsic coagulation system. It is one of the most active procoagulant substances in the body, and plays an important role in physiological hemostasis, coagulation process and various thromboembolic diseases. However, as the only transmembrane glycoprotein expressed on the cell surface in the blood coagulation system, whether TF has receptor properties and non-coagulation function has gradually become the focus of many scholars. Recent studies have shown that TF has th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K39/29C12N15/70A61P35/00
Inventor 刘文涛吴雪丰徐礼友杨政
Owner JIANGSU HIGH WIT BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com